Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Culmerciclib plus endocrine therapy vs mono-chemotherapy in HR+/HER2- advanced breast cancer with aggressive disease and high visceral tumor burden
ChiCTR2600126435Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of culmerciclib in breast cancer (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600126435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126435.